ADAG
Companies
NASDAQ
Adagene Inc.
Health Care
$1.94
-$0.05 (-2.51%)
Price Chart
Overview
About ADAG
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Market Cap
$131.6M
Volume
33.5K
Avg. Volume
30.5K
P/E Ratio
-2.2608695
Dividend Yield
0.00%
Employees
113.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.31
Low Correlation
Volatility
High (0.88)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ADAG shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$131.6M
Volume33.5K
P/E Ratio-2.26
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 30, 2022Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025